Daiwa Securities Group
MRNA icon

Daiwa Securities Group’s Moderna MRNA Stock Holding History

Daiwa Securities Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.14M Sell
30,535
-3,340
-10% -$173K ﹤0.01% 681
2026
Q1 		$1.72M Buy
33,875
+5,980
+21% +$279K ﹤0.01% 676
2025
Q4 		$823K Sell
27,895
-3,635
-12% -$98.8K ﹤0.01% 814
2025
Q3 		$815K Buy
31,530
+6,883
+28% +$192K ﹤0.01% 797
2025
Q2 		$680K Sell
24,647
-23,643
-49% -$623K ﹤0.01% 806
2025
Q1 		$1.37M Sell
48,290
-2,975
-6% -$106K 0.01% 676
2024
Q4 		$2.13M Sell
51,265
-18,926
-27% -$905K 0.01% 579
2024
Q3 		$4.69M Buy
70,191
+10,960
+19% +$1.01M 0.02% 393
2024
Q2 		$7.03M Buy
59,231
+5,309
+10% +$672K 0.04% 270
2024
Q1 		$5.75M Buy
53,922
+5,022
+10% +$506K 0.03% 297
2023
Q4 		$4.86M Buy
48,900
+2,476
+5% +$208K 0.03% 309
2023
Q3 		$4.79M Buy
46,424
+5,930
+15% +$661K 0.03% 283
2023
Q2 		$4.92M Sell
40,494
-549
-1% -$73.2K 0.03% 284
2023
Q1 		$6.3M Buy
41,043
+1,645
+4% +$271K 0.04% 224
2022
Q4 		$7.08M Buy
39,398
+713
+2% +$117K 0.05% 198
2022
Q3 		$4.58M Buy
38,685
+1,390
+4% +$211K 0.04% 261
2022
Q2 		$5.33M Buy
37,295
+1,391
+4% +$199K 0.04% 236
2022
Q1 		$6.18M Buy
35,904
+3,336
+10% +$562K 0.04% 235
2021
Q4 		$8.27M Buy
32,568
+2,569
+9% +$751K 0.05% 202
2021
Q3 		$11.5M Buy
29,999
+6,740
+29% +$2.49M 0.08% 138
2021
Q2 		$5.46M Buy
23,259
+1,924
+9% +$344K 0.04% 222
2021
Q1 		$2.79M Buy
21,335
+2,873
+16% +$416K 0.02% 339
2020
Q4 		$1.93M Sell
18,462
-378
-2% -$38.2K 0.01% 400
2020
Q3 		$1.33M Buy
18,840
+16,965
+905% +$1.18M 0.01% 436
2020
Q2 		$56K Hold
1,875
– – ﹤0.01% 907
2020
Q1 		$56K Sell
1,875
-6
-0.3% -$138 ﹤0.01% 960
2019
Q4 		$37K Buy
+1,881
New +$33.4K ﹤0.01% 979

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Daiwa Securities Group's MRNA Position: Q2 2026 in Review

Daiwa Securities Group reduced its Moderna (MRNA) stake by 9.9% in Q2 2026, selling an estimated $173K and leaving 30,535 shares worth $2.14M. The position accounts for ﹤0.01% of the portfolio, ranked #681.

Daiwa Securities Group first reported a position in MRNA in Q4 2019 and has held it in 27 quarters since. The position peaked at $11.5M in Q3 2021. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Daiwa Securities Group held 30,535 shares of Moderna worth $2.14M as of Q2 2026.
  • Daiwa Securities Group sold 3,340 Moderna shares in Q2 2026, an estimated $173K.
  • Moderna made up ﹤0.01% of Daiwa Securities Group's portfolio in Q2 2026, its #681 holding.
  • Daiwa Securities Group first reported a position in Moderna in Q4 2019 and has held it in 27 quarters since.
  • Daiwa Securities Group's Moderna position peaked at $11.5M in Q3 2021.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Daiwa Securities Group's 13F filing for Q2 2026, filed 31 Jul 2026.